Allakos: Potential For Comeback With Lirentelimab With 2 Indications (NASDAQ:ALLK)
seekingalpha.com
finance
2022-10-18 07:22:52

Mongkolchon Akesin/iStock via Getty Images Allakos (NASDAQ:ALLK) is a great speculative biotech play to look into. The reason why I think it has potential value is because it has two major data readouts in the 2nd half of 2023. It suffered a setback with the use of its drug lirentelimab back in September of 2022, when it had announced that a phase 3 study treating patients with eosinophilic duodenitis failed to achieve statistical significance in the patient reported symptomatic co-primary endpoint.
